Keystone Capital Launches Gillson Sciences to Address Growing Demand for Laboratory Testing and Compliance Services

Keystone Capital Management has unveiled Gillson Sciences, a Chicago-based entity dedicated to providing laboratory testing, monitoring, and advisory solutions. This initiative is designed to cater to the pharmaceuticals, biopharma, medical devices, healthcare, and environmental sciences industries, ensuring their products adhere to the highest safety and efficacy standards. The establishment of Gillson Sciences represents a pivotal advancement in tackling intricate human health issues through comprehensive scientific approaches.

Following the acquisitions of Azzur Labs and Micro Measurement Laboratories in January 2025, now operating under the Gillson Testing banner, Gillson Sciences has significantly expanded its service offerings. These acquisitions enable Gillson to meet the rigorous requirements set by regulatory authorities, positioning it as an indispensable ally for clients facing the complex compliance landscape of their respective fields. With facilities in Pennsylvania, Illinois, and California, alongside a nationwide team of field experts, Gillson is strategically equipped to deliver its services across the United States.

Jason Fischer, appointed as CEO, brings over a decade of leadership experience from UL Solutions to Gillson Sciences. His background in corporate development and strategic acquisitions is anticipated to propel Gillson's growth in the testing, inspection, certification, and compliance industry. The company's ambition to lead the market is grounded in its dedication to scientific rigor, data accuracy, and unparalleled customer service.

The collaboration between Keystone Capital and Fischer reflects a mutual commitment to establishing a platform that emphasizes quality, safety, and regulatory compliance. Todd Lanscioni, Managing Director at Keystone Capital, has voiced strong support for Fischer's leadership and the Gillson team's capacity to realize this ambitious vision. As Gillson Sciences seeks to broaden its horizons, its core objective remains unwavering: to enhance human health through top-tier laboratory testing and advisory services.

This announcement is timely, coinciding with an unprecedented surge in the need for dependable testing and compliance services. Factors such as heightened regulatory oversight and the imperative for safe, effective healthcare and environmental products are driving this demand. Gillson Sciences is ready to confront these challenges, equipping clients with the necessary expertise and support to navigate the dynamic industry landscape successfully.